Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Nova Psychiatry Inc

Neither a doctor nor a teaching hospital

Research payments

$518,137

105 payments

Through program year 2025, Nova Psychiatry Inc is reported as receiving $518,137 in research payments, across 105 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $187,095 28
2024 Research $86,211 4
2023 Research $177,969 57
2022 Research $53,838 14
2021 Research $775 1
2020 Research $12,249 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $248,754 25 payments
  2. LivaNova USA, Inc. $142,202 29 payments
  3. Janssen Research & Development, LLC $85,640 8 payments
  4. AbbVie, Inc. $16,506 2 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $13,024 2 payments
  6. Boehringer Ingelheim RCV GmbH & Co KG $10,688 4 payments
  7. Sumitomo Pharma America, Inc. $1,324 35 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $125,439 25 payments
  2. Connex 3 $88,280 7 payments
  3. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $77,498 6 payments
  4. Connex-3 $58,878 2 payments
  5. An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) $56,922 9 payments
  6. A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) $28,027 9 payments
  7. Connex-X $27,334 2 payments
  8. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $16,763 4 payments
  9. A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder $15,000 1 payment
  10. A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $12,249 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record